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Selective internal radiation therapy (SIRT) with yttrium-90
(90Y) microspheres is a promising treatment option
for unresectable neuroendocrine tumour liver meta-
stases (NETLM). Liver metastases, which present in
46−93% of patients at time of diagnosis depending of
origin of the primary tumour, are a cause of signiﬁcant
mortality and morbidity. For this reason, patients with
NETLM require optimal clinical management, using the
combined skills of a multidisciplinary team.
The options available can be categorised as follows:
• Surgical, with or without ablation, e.g. RFA
• Medical, e.g. somatostatin analogues and/or chemo-
therapy
• Nuclear medicine, e.g. Peptide Receptor Radionuclide
Therapy (PRRT)
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• Liver-directed therapies, e.g.
(a) Transcatheter Arterial bland Embolisation (TAE),
(b) Transcatheter Arterial Chemoembolisation (TACE)
◦ Conventional TACE
◦ Drug eluting beads (DEB)
(c) Selective Internal Radiation Therapy (SIRT) with 90Y
microspheres
2. Treatment approaches
The treatment approach to NETLM is dictated by the
pattern of disease within the liver and beyond.
2.1. Liver metastases without extra-hepatic spread
Morphologically, there are three different patterns of liver
metastases:
(A) Simple Pattern: The metastases are conﬁned to one
liver lobe or limited to two adjacent segments. This
“simple pattern” occurs in 20−25% of patients and is
generally amenable to either:
(a) Surgery − minor or anatomical resection with or
without ablation, e.g. RFA, OR
1359-6349 © 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
68 ejc supplements 10, no. 3 (2012) 67–69
Table 1 – Summary of the clinical literature on SIRT in NETLM
Investigator n Therapy ORR SD Symp. PFS Median survival
Kennedy 2 148a SIR-Spheresb 63.2% 22.7% nr 70mo
King 3 34 SIR-Spheresb + 5-FU 50% 14.7% 55% nr 59% at 35.2mo
Saxena 4 48 SIR-Spheresb 54% 23% nr nr 35mo
Cao 5 58a SIR-Spheresb + 5-FU 39.2% 27.4% nr nr 36mo
Jahangir 6 73a SIR-Spheresb nr nr nr 10.6mo 55.2mo
Rhee 7 42 90Y microspheres [92−94%]c nr nr 22d & 28b mo
Meranze 8 10 SIR-Spheresb 40% 60% nr nr 70% at 28mo
Jakobs 9 25a SIR-Spheresb 20.8% 75% 92% nr 96% at 12mo
McGrath 10 26a SIR-Spheresb 58.3%e 33%e 2 of 3 nr 69.1% at 17mo
Kennedy 11 18a SIR-Spheresb 89%e nr nr nr 89% at 27mo
Coldwell 12 84a 90Y microspheres 67% 33% 80% nr nr
Kalinowski 1 9 SIR-Spheresb 67% 33% ↑ QoL 11mo 57% at 36mo
Murthy 13 8a SIR-Spheresb 12.5% 50% nr nr 14mo
Paprottka 14 42a SIR-Spheresb 22.5% 75% 94.7% nr 95% at 16.2mo
mo: months; nr: not reported; Symp: symptomatic response.
a Retrospective data. b 90Y resin microspheres. c ORR + SD. d 90Y glass microspheres. e Imaging + CgA.
(b) Liver-directed therapy if the patient is not ﬁt for
surgery.
(B) Complex Pattern: One major lesion but with smaller
satellite lesions contra-laterally. This “complex bi-
lobar pattern” occurs in 10−15% of the cases. Patients
are treated with either:
(a) Surgery − major one-step or two-step resection/
ablation, OR
(b) Liver-directed therapy if patients are not ﬁt for
surgery.
(C) Diffuse Pattern: There are diffuse, multifocal liver
metastases. This “diffuse pattern” occurs in 60−70%
of the cases. Patients with this pattern of disease
are unresectable and are generally treated with liver-
directed therapy.
2.2. Liver metastases with extra-hepatic spread
Inoperable NETLM with extra-hepatic spread should
initially be treated using non-surgical methods (e.g.
biotherapy, chemotherapy, PRRT etc.) regardless of the
extent of liver disease, and may be combined with
liver-directed therapy such as SIRT, as appropriate.
Surgical debulking may also be undertaken for selected
candidates.
3. SIRT
The following conclusions can be drawn from the
literature on SIRT in NETLM (see Table 1):
• Sufﬁcient evidence exists to support the safety and
effectiveness of SIRT for unresectable NETLM.
• Statistical signiﬁcance was achieved when deter-
mining overall survival, suggesting that locoregional
control of NETLM with SIRT may be of paramount
importance for overall survival.
• The incidence of adverse events with SIRT is low,
without evidence of treatment-related grade 4 events
or radiation-induced liver disease (RILD).
• Overall survival was related to: the extent of tumour
involvement, the presence of extrahepatic disease at
the time of SIRT, good radiological tumour response
(CR+PR), and histological grade of the tumour.
4. Conclusions
SIRT with 90Y microspheres is a promising treatment
option for unresectable NETLM. Patients with low
hepatic tumour burden, well-differentiated tumour and
no extrahepatic disease are the best candidates for SIRT.
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